Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Retatrutide, a GIP, GLP1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, doubleblind, placebo and activecontrolled, parallelgroup, phase 2 trial conducted in the USA
Here are some key aspects of GLP-1 agonists: Target appetite reduction Mimic natural GLP-1 Support sustained weight loss Benefit metabolic health Reduce cardiovascular risks These drugs are part of a growing trend to incorporate medication into weight management strategies
If nausea is persistent, severe, or keeps you from eating and drinking, contact your healthcare provider
Do not take other medicines unless they have been discussed with your doctor
It also provides calcium , iron , and potassium to support bone and heart health
